Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-03-13
2007-03-13
Huff, Sheela J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C530S391100
Reexamination Certificate
active
10632388
ABSTRACT:
The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising:a) selecting at least one peptide that modulates the activity of a protein of interest; andb) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide.Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display,E. colidisplay, ribosome display, RNA-peptide screening, or chemical-peptide screening.
REFERENCES:
patent: 3691016 (1972-09-01), Patel
patent: 3941763 (1976-03-01), Sarantakis
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4289872 (1981-09-01), Denkewalter et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5229490 (1993-07-01), Tam
patent: 5284656 (1994-02-01), Platz et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5338665 (1994-08-01), Schatz et al.
patent: 5376367 (1994-12-01), Williams
patent: 5428130 (1995-06-01), Capon et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5498530 (1996-03-01), Schatz et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5565335 (1996-10-01), Capon et al.
patent: 5608035 (1997-03-01), Yanofsky et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5726290 (1998-03-01), Bodary et al.
patent: 5733731 (1998-03-01), Schatz et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5767234 (1998-06-01), Yanofsky et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5786331 (1998-07-01), Barrett et al.
patent: 5792451 (1998-08-01), Sarubbi et al.
patent: 5840844 (1998-11-01), Lasky et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5869452 (1999-02-01), Ng et al.
patent: 5877151 (1999-03-01), Pereira
patent: 5880096 (1999-03-01), Barrett et al.
patent: 5922545 (1999-07-01), Mattheakis et al.
patent: 5932546 (1999-08-01), Barrett et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6117655 (2000-09-01), Capon et al.
patent: 0 173 494 (1986-03-01), None
patent: 0 325 224 (1989-07-01), None
patent: 0 526 452 (1993-02-01), None
patent: 0 585 287 (1994-03-01), None
patent: 0 911 393 (1999-04-01), None
patent: 0 714 912 (1999-05-01), None
patent: 1 029 870 (2000-08-01), None
patent: WO 93/21259 (1993-10-01), None
patent: WO 94/07921 (1994-04-01), None
patent: WO 95/09917 (1995-04-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO 95/18858 (1995-07-01), None
patent: WO 95/21919 (1995-08-01), None
patent: WO 95/21920 (1995-08-01), None
patent: WO 95/26746 (1995-10-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/11214 (1996-04-01), None
patent: WO 96/11953 (1996-04-01), None
patent: WO 96/17942 (1996-06-01), None
patent: WO 96/18412 (1996-06-01), None
patent: WO 96/23899 (1996-08-01), None
patent: WO 96/30057 (1996-10-01), None
patent: WO 96/32478 (1996-10-01), None
patent: WO 96/40189 (1996-12-01), None
patent: WO 96/40750 (1996-12-01), None
patent: WO 96/40772 (1996-12-01), None
patent: WO 96/40987 (1996-12-01), None
patent: WO 97/00270 (1997-01-01), None
patent: WO 97/08203 (1997-03-01), None
patent: WO 97/08553 (1997-03-01), None
patent: WO 97/23614 (1997-07-01), None
patent: WO 97/28828 (1997-08-01), None
patent: WO 97/31019 (1997-08-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/35989 (1997-10-01), None
patent: WO 97/40070 (1997-10-01), None
patent: WO 97/44453 (1997-11-01), None
patent: WO 98/09985 (1998-03-01), None
patent: WO 98/10795 (1998-03-01), None
patent: WO 98/15833 (1998-04-01), None
patent: WO 98/24477 (1998-06-01), None
patent: WO 98/25965 (1998-06-01), None
patent: WO 98/28427 (1998-07-01), None
patent: WO 98/31820 (1998-07-01), None
patent: WO 98/33812 (1998-08-01), None
patent: WO 98/46257 (1998-10-01), None
patent: WO 98/53842 (1998-12-01), None
patent: WO 98/55620 (1998-12-01), None
patent: WO 99/05302 (1999-02-01), None
patent: WO 99/14244 (1999-03-01), None
patent: WO 99/17789 (1999-04-01), None
patent: WO 99/18243 (1999-04-01), None
patent: WO 99/18781 (1999-04-01), None
patent: WO 99/24462 (1999-05-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/24770 (2000-05-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 01/02440 (2001-01-01), None
Abuchowski et al. (1981), “Soluble Polymer—Enzyme Adducts,”Enzymes as Drugs: Chapter 13, Hocenberg and Roberts, eds., Wiley-Interscience, New York, NY, pp. 367-383.
Adjei et al. (1990), “Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers,”Pharmaceutical Research7:565-569.
Adjei et al. (1990), “Bioavailability of leuprolide following intratracheal administration to beagle dogs,”International Journal of Pharmaceutics61:135-144.
Alexander et al. (1996), “Deficiencies in Progenitor Cells of Multiple Hematopoietic Lineages and Defective Megakaryocytopoiesis in Mice Lacking the Thrombopoietin Receptor c-Mpl,”Blood87:2162-2170.
Bartley et al. (1994), “Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl,”Cell77:1117-1124.
Basser et al. (1996), “Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer,”The Lancet348:1279-1281.
Braquet et al. (1989), “Effect of Endothelin-1 on Blood Pressure and Bronchopulmonary System of the Guinea Pig,”Journal of Cardiovascular Pharmacology, 13 (Suppl.5):S143-S146.
Carosella et al. (1990), “Anti-Human Interleukin 2 Receptor Monoclonal Antibody Isotypic Switching: Chimeric Rat-Human Antibodies,”Human Immunology29:233-246.
Chang et al. (1995), “Cloning and Characterization of ht eHuman Megakaryocyte Growth and Development Factor (MGDF) Gene,”The Journal of Biological Chemistry270:511-514.
Choi et al. (1995), “Platelets Generated In Vitro From Proplatelet-Displaying Human Megakaryocytes are Functional,”Blood85:402-413.
Clackson et al. (1995), “A Hot Spot of Binding Energy in a Hormone-Receptor Interface,”Science267:383-386.
Creighton, Thomas E., Proteins: Structures and Molecular Principles, W.H. Freeman and Company, New York, pp. 70-86 (1983).
Davis et al. (1985), “Preparatioin and Characterization of Antibodies with Specificity for the Amino-Terminal Tetrapeptide Sequence of the Platelet-Derived Connective Tissue,”Biochemistry International10:395-4404.
Debili et al., (1995) “The Mpl Receptor is Expressed in the Megakaryocytic Lineage From Late Progenitors to Platelets,”Blood85:391-401.
Debs et al. (1988), “Lung-Specific Delivery of Cytokines Induces Sustained Pulmonary and Systemic Immunomodulation in Rats,”The Journal of Immunology140:3482-3488.
de Sauvage et al. (1994), “Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand,”Nature369:533-538.
Ellison et al. (1982), “The nucleotide sequence of a human immunoglobulin Cγ1gene,”Nucleic Acids Research10:4071-4079.
Erickson et al., The Proteins, 3rded., 2: Chapter 3, Solid-Phase Peptide Synthesis, Neurath et al., eds., Academic Press, New York, pp. 255-527 (1976).
Finn et al., The Proteins, 3rded., 2: Chapter 2, Solid-Phas
Amgen Inc.
Gaul Timothy J.
Huff Sheela J.
LandOfFree
Modified peptides as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified peptides as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified peptides as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3775299